ArticleInternational journal of urology : official journal of the Japanese Urological Association2026
Risk Assessment of Non-Urinary Tract Recurrence After Radical Nephroureterectomy Based on CheckMate 274 Trial Eligibility: A Multicenter Retrospective Study.
Article in International journal of urology : official journal of the Japanese Urological Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo assess the risk of non-urinary tract recurrence after radical nephroureterectomy for patients with upper urinary tract carcinoma according to CheckMate 274 trial eligibility.
methodsWe evaluated patients who underwent radical nephroureterectomy between 2012 and 2022 for upper urinary tract carcinoma. Recurrence was defined as extra-urinary tract recurrence. Univariate and multivariable analyses were used to determine the risk factors for recurrence according to CheckMate 274 trial eligibility.
resultsAmong 545 patients, 127 (23.3%) experienced recurrence during the follow-up period. Three-hundred sixty two (66.4%) patients were not eligible for CheckMate 274 trial criteria while 183 (33.6%) patients were eligible. The multivariable analysis demonstrated that preoperative renal dysfunction (HR2.24, 95% CI: 1.37-3.65, p = 0.001), presence of lymphovascular invasion (HR1.89, 95% CI: 1.18-3.00, p = 0.008)., positive resection margin (HR2.58, 95% CI: 1.43-4.66, p = 0.002), positive lymph node status (HR: 2.34, 95% CI: 1.21-4.55, p = 0.012) were risk factors for CheckMate 274 eligible patients. On the other hand, among 362 ineligible patients, performing preoperative diagnostic ureteroscopy (HR 3.09, 95% CI: 1.55-6.17, p = 0.001), presence of lymphovascular invasion (HR3.81, 95% CI: 1.78-8.17, p < 0.001), presence of histological subtype (HR4.82, 95% CI: 1.91-12.13, p < 0.001) and pathological T2 stage (HR2.28, 95% CI: 1.08-4.81, p = 0.031) were risk factors for recurrence.
conclusionsAccording to our study, it may be possible to discuss the needs of adjuvant treatment in each individual. These findings provide a basis for more informed decisions regarding adjuvant therapy in UTUC, with the potential to reduce unnecessary treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.